Search for: "Clinical Data, Inc."
Results 501 - 520
of 997
Sorted by Relevance
|
Sort by Date
12 Oct 2018, 1:24 pm
Apotex, Inc., 550 F.3d 1075, 1086 (Fed. [read post]
29 Apr 2022, 11:10 am
Solutions Law Press, Inc. invites you to receive future updates by registering here and participating and contributing to the discussions in our Solutions Law Press, Inc. [read post]
31 Dec 2015, 5:12 am
Medtronic, Inc., 188 Cal. [read post]
9 Jan 2017, 4:07 pm
On November 16, 2016, Endologix announced that the FDA requested two-year follow-up data on patients enrolled in the EVAS-FORWARD-IDE study to assess Nellix. [read post]
6 Jul 2017, 4:24 am
The $$ quote follows: Ransomware poses an existential threat to data security and operations in an era of electronic health records, integrated health data management systems and connected medical devices. [read post]
12 Aug 2020, 5:56 am
BioTelemetry Inc. [read post]
5 Jul 2013, 5:00 am
Squibb and Sons, Inc. v. [read post]
29 Nov 2023, 5:00 am
In Allgenesis Biotherapeutics Inc. v. [read post]
25 Mar 2024, 6:38 am
About Solutions Laws Press, Inc. [read post]
18 Jan 2024, 9:16 am
The Federal Circuit noted that Defendants’ ANDA labels carved out “the superiority data in the clinical studies portion of the label and the cross-reference to that data” without “even referenc[ing] the patient class recited” in claim 7 of the ’096 patent. [read post]
19 Apr 2010, 10:04 pm
Wal-Mart Stores, Inc. [read post]
22 Jan 2015, 1:47 pm
Grant himself opined, SEC does not exclusively provide Mp—both Mn and Mw can also be obtained from the data generated by the SEC method after some calculations. [read post]
27 May 2008, 6:41 am
Cargill, Inc. v. [read post]
18 Apr 2011, 12:40 pm
(SeeWARNINGS and CLINICAL PHARMACOLOGY, Transdermal versus OralContraceptives.) [read post]
Parker McDonald Reports on the MHRA Releasing New Advice for Metal-On-Metal Hip Replacement Patients
5 Mar 2012, 1:35 pm
This recall came after data from the National Joint Registry of England and Wales indicated that the five-year failure rate of these products is approximately 13 percent, or 1 in 8 patients. [read post]
9 Aug 2021, 6:17 am
Aaron Kesselheim of Harvard-affiliated Brigham and Women’s Hospital, who resigned as a member of the FDA advisory panel that reviewed and voted against approval of Biogen’s drug prior to the FDA” approval, “said more information is needed on FDA’s role in Biogen’s evaluation of clinical trial data, as well as why the agency decided to base its approval on a ‘surrogate’ biomarker rather than the drug’s impact on cognitive… [read post]
2 Oct 2009, 8:33 pm
In 2002, InterMune issued a press release regarding a clinical study that supposedly showed benefits for some IPF patients. [read post]
9 Oct 2014, 1:46 pm
According to the complaints, both companies relied on unblinded, uncontrolled clinical trials “with significant methodological flaws” and then exaggerated the results. [read post]
9 Aug 2011, 9:29 am
No data has been released regarding these complaints. [read post]
11 Jun 2020, 9:46 am
Flatiron and Tempus are competitors in the health technology space that specialize in collecting and analyzing clinical and molecular data. [read post]
